Zhu H - Search Results

1

A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.

Huang M, Zhu H, Yi C, Yan J, Wei L, Yang X, Chen S, Huang Y. Huang M, et al. Among authors: zhu h. Cancer Chemother Pharmacol. 2018 Nov;82(5):829-838. doi: 10.1007/s00280-018-3658-9. Epub 2018 Aug 24. Cancer Chemother Pharmacol. 2018. PMID: 30167846

2

DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells.

Lu HR, Meng LH, Huang M, Zhu H, Miao ZH, Ding J. Lu HR, et al. Among authors: zhu h. Cancer Chemother Pharmacol. 2005 Mar;55(3):286-94. doi: 10.1007/s00280-004-0877-z. Epub 2004 Nov 16. Cancer Chemother Pharmacol. 2005. PMID: 15592835

3

Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase.

Lu HR, Zhu H, Huang M, Chen Y, Cai YJ, Miao ZH, Zhang JS, Ding J. Lu HR, et al. Among authors: zhu h. Mol Pharmacol. 2005 Oct;68(4):983-94. doi: 10.1124/mol.105.011544. Epub 2005 Jul 15. Mol Pharmacol. 2005. PMID: 16024664

4

Medicinal chemistry of probimane and MST-16: comparison of anticancer effects between bisdioxopiperazines.

Lu DY, Huang M, Xu CH, Zhu H, Xu B, Ding J. Lu DY, et al. Among authors: zhu h. Med Chem. 2006 Jul;2(4):369-75. doi: 10.2174/157340606777724095. Med Chem. 2006. PMID: 16848748

5

Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.

Huang M, Gao H, Chen Y, Zhu H, Cai Y, Zhang X, Miao Z, Jiang H, Zhang J, Shen H, Lin L, Lu W, Ding J. Huang M, et al. Among authors: zhu h. Clin Cancer Res. 2007 Feb 15;13(4):1298-307. doi: 10.1158/1078-0432.CCR-06-1277. Epub 2007 Feb 7. Clin Cancer Res. 2007. PMID: 17287296

6

R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.

Zhu H, Huang M, Yang F, Chen Y, Miao ZH, Qian XH, Xu YF, Qin YX, Luo HB, Shen X, Geng MY, Cai YJ, Ding J. Zhu H, et al. Mol Cancer Ther. 2007 Feb;6(2):484-95. doi: 10.1158/1535-7163.MCT-06-0584. Mol Cancer Ther. 2007. PMID: 17308047

7

Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.

Huang M, Miao ZH, Zhu H, Cai YJ, Lu W, Ding J. Huang M, et al. Among authors: zhu h. Mol Cancer Ther. 2008 Jun;7(6):1440-9. doi: 10.1158/1535-7163.MCT-07-2116. Mol Cancer Ther. 2008. PMID: 18566216

8

Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H2O2 generation and topoisomerase II inhibition.

Cai YJ, Lu JJ, Zhu H, Xie H, Huang M, Lin LP, Zhang XW, Ding J. Cai YJ, et al. Among authors: zhu h. Free Radic Biol Med. 2008 Sep 1;45(5):627-35. doi: 10.1016/j.freeradbiomed.2008.05.017. Epub 2008 May 28. Free Radic Biol Med. 2008. PMID: 18582559

9

Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol.

Zhu H, Ding WJ, Wu R, Weng QJ, Lou JS, Jin RJ, Lu W, Yang B, He QJ. Zhu H, et al. Cancer Invest. 2010 Jan;28(1):23-32. doi: 10.3109/07357900903095664. Cancer Invest. 2010. PMID: 19916747

10

Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo.

Ding W, Cai T, Zhu H, Wu R, Tu C, Yang L, Lu W, He Q, Yang B. Ding W, et al. Among authors: zhu h. Cancer Lett. 2010 Jul 28;293(2):158-66. doi: 10.1016/j.canlet.2010.01.005. Epub 2010 Feb 6. Cancer Lett. 2010. PMID: 20137855

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30,298 results

Search Page

Filters